ライフサイエンスコーパス: somnolence

1 derate constipation, weakness or fatigue, or somnolence.

2 the most common being headache, fatigue, and somnolence.

3 these also cause other effects, most notably somnolence.

4 group were headache, dizziness, nausea, and somnolence.

5 f mental status, respiratory depression, and somnolence.

6 sidone were nausea, headache, akathisia, and somnolence.

7 , activated partial thromboplastin time, and somnolence.

8 he control and AgRP KO mice, probably due to somnolence.

9 e unpleasant taste, headache, dry mouth, and somnolence.

10 se events were asthenia, anorexia, pain, and somnolence.

11 The dose-limiting toxicity was somnolence.

12 vent reported among risperidone patients was somnolence.

13 ring risperidone treatment were headache and somnolence.

14 pine were dry mouth, increased appetite, and somnolence.

15 ommon treatment-emergent adverse events were somnolence (10.0%), akathisia (7.7%), and sedation (7.7%

16 (12 of 205 [5.9%] and 3 of 196 [1.5%]), and somnolence (11 of 205 [5.4%] and 5 of 196 [2.6%]).

17 1 (65.3%)), most commonly dizziness (23.1%), somnolence (16.5%), headache (14.0%).

18 d vasodilation (63%), paresthesia (86%), and somnolence (17%).

19 s 4 [4.9%] in the control group; P<.001) and somnolence (19 [23%] in the gabapentin group vs 5 [6%] i

20 of Parkinson's disease (22 [11%] vs 4 [9%]), somnolence (20 [10%] vs 3 [6%]), dyskinesia (18 [9%] vs

21 and also experienced more treatment-emergent somnolence (21 patients [38.2%] vs 5 [8.3% ], respective

22 oups included weight gain (24.8% and 36.2%), somnolence (21.2% and 18.1%), dry mouth (12.8% and 8.0%)

23 ve 180 mug, 120 mug, and placebo groups were somnolence (21.4% and 20.6% vs 4.8%); dry mouth (4.8% an

24 ents included decreased appetite (59 [22%]), somnolence (33 [13%]), and fatigue (33 [13%]).

25 The most common adverse events reported were somnolence (33%), headache (33%), rhinitis (28%), and we

26 alopram (P < .05 vs placebo) were fatigue or somnolence (35 patients [41.1%]), sleep disturbance (12

27 mong patients receiving thalidomide included somnolence (4 patients), rash (2 patients), and peripher

28 recipients vs. 14.5% of placebo recipients), somnolence (5.1% vs. 1.5%), and dry mouth (5.1% vs. 0.8%

29 sidone and placebo groups, respectively) and somnolence (5.5% and 1.0%).

30 s (9%), leukopenia (7%), hyperglycemia (7%), somnolence (6%), thrombocytopenia (5%), and depression (

31 spectively, were tremor (13.9%, 5.0%, 7.5%), somnolence (8.9%, 11.9%, 1.3%), insomnia (10.1%, 9.4%, 1

32 in (15.3% vs 2.3%), fatigue (13.7% vs 0.0%), somnolence (9.9% vs 1.5%), and hypersalivation (9.9% vs

33 t in the augment-aripiprazole group included somnolence, akathisia, and weight gain.

34 n (grade 4), raised bilirubin, vomiting, and somnolence (all grade 3).

35 iatric, gastrointestinal adverse events, and somnolence among others (GRADE=moderate).

36 Adverse effects included somnolence and dizziness with TCAs, SNRIs, and anticonvu

37 dose-related, and evolved from complaints of somnolence and dizziness, to more pronounced signs and s

38 The most common adverse events were somnolence and dizziness.

39 s reported for pregabalin and lorazepam were somnolence and dizziness.

40 ns with risk included disorders of excessive somnolence and frequency of nightmares.

41 scriminatory for the presentation of daytime somnolence and gait ataxia.

42 Adverse events with SEP-363856 included somnolence and gastrointestinal symptoms; one sudden car

43 patients with symptoms of excessive daytime somnolence and low AHI this may help diagnose the UARS a

44 Somnolence and nausea were the only treatment-emergent a

45 The most common TEAEs were headache and somnolence and nearly all TEAEs were mild in severity.

46 Dose-limiting toxicities included somnolence and neuropathy.

47 nts were CNS-related and included dizziness, somnolence and paraesthesia.

48 of mild headache and 2 weeks of progressive somnolence and photophobia accompanied by binocular hori

49 isturbances, in particular excessive daytime somnolence and rapid eye movement sleep behavioural diso

50 erse effects noted with thalidomide included somnolence and rash (7 patients each), and 6 of the 29 p

51 ese studies showed adverse effects, however, somnolence and weight gain particularly being associated

52 (SICU stay </=24 hours, airway concerns, and somnolence) and disposition delays (end-of-life decision

53 cluded diarrhea, vomiting, fatigue, pyrexia, somnolence, and abnormal results on liver-function tests

54 se nausea, vomiting, dehydration, confusion, somnolence, and coma.

55 th nausea, vomiting, dehydration, confusion, somnolence, and coma.

56 ased appetite, diarrhoea, fatigue, lethargy, somnolence, and decreased weight.

57 9%) and tremor, speech disorder, dizziness, somnolence, and disorientation (each 4%).

58 ven LY334370 than placebo reported asthenia, somnolence, and dizziness.

59 The most common adverse events were nausea, somnolence, and dry mouth (reported in 0.4 to 4.1%); the

60 ommonly reported adverse events were nausea, somnolence, and dry mouth.

61 e headache, dizziness, nausea, dissociation, somnolence, and nasopharyngitis.

62 on weekdays and weekends, diurnal subjective somnolence, and substance consumption.

63 on adverse events were nausea, vomiting, and somnolence, and these occurred more often in the TDF gro

64 te for placebo were extrapyramidal disorder, somnolence, and tremor.

65 pophosphatemia/hypokalemia, neutropenia, and somnolence at 40 mg/m(2); and urticaria at 55 mg/m(2).

66 match was associated with diurnal subjective somnolence (beta = 0.073; p < 0.001) and specific sleep-

67 rder narcolepsy is associated with excessive somnolence, cataplexy and increased propensity for rapid

68 multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy.

69 Importantly, no significant somnolence, constipation, or neuropathy has been seen in

70 atients with PBC, with the degree of daytime somnolence correlating strongly with the degree of fatig

71 In 75 treated patients (213 trials), somnolence decreased using stimulants (mainly amphetamin

72 Dizziness, nausea, somnolence, diplopia, fatigue, and rash were each report

73 adverse events (>=10%) with zuranolone were somnolence, dizziness, and sedation.

74 Somnolence, dizziness, ataxia, peripheral edema, and inf

75 Somnolence, dizziness, dry mouth, and weight gain occurr

76 er zuranolone+ADT or placebo+ADT groups were somnolence, dizziness, headache, and nausea.

77 f dry mouth, dizziness/light-headedness, and somnolence/drowsiness.

78 frequently during olanzapine treatment were somnolence, dry mouth, increased appetite, weight gain,

79 wn side effects of the drug (e.g., headache, somnolence, dry mouth, nausea, and dizziness).

80 te in the placebo+ADT group) were dizziness, somnolence, dry mouth, nausea, diarrhea, and fatigue; 12

81 for the olanzapine cotherapy group included somnolence, dry mouth, weight gain, increased appetite,

82 pressed in terms that do not directly denote somnolence (e.g. 'tiredness' or 'fatigue').

83 ion-site dryness, application-site pain, and somnolence (each reported by 4 patients [8%]).

84 usea, headache, constipation, dizziness, and somnolence, each occurred in >=10% of patients.

85 sleep structure and cause excessive day-time somnolence (EDS).

86 correlates to symptoms of excessive daytime somnolence (EDS).

87 low alcohol consumption, depression, daytime somnolence, epilepsy and earlier menarche.

88 Both degree of daytime somnolence (ESS) and actual daytime sleep activity (acce

89 Dose-limiting reactions were neurologic (somnolence, euphoria, ataxia) and associated with the in

90 luded dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsine

91 d nausea, constipation, dizziness, vomiting, somnolence, fatigue, and sedation.

92 Other serious adverse events were somnolence, fever and hypotension, and rash in three pat

93 The valproate group had higher rates of somnolence, gait disturbance, tremor, diarrhea, and weak

94 umonia, gastrointestinal adverse events, and somnolence (GRADE=moderate).

95 n=2), quality of life, and increased risk of somnolence (GRADE=moderate).

96 reased risk of dizziness, dry mouth, nausea, somnolence (GRADE=moderate).

97 lated adverse events were dizziness, tremor, somnolence, headache, nausea, and rash.

98 ermore, while KOR antagonists do not promote somnolence in the absence of pain, they normalized disru

99 1), suggesting significantly greater daytime somnolence in the patients with PBC.

100 significant predictive value of sex, daytime somnolence, insomnia, restless legs syndrome, sleep apno

101 Somnolence is the major toxicity.

102 bnormality, in the form of excessive daytime somnolence, is present in a significant proportion of pa

103 Dose-limiting toxicities were somnolence (n = 1), confusion (n = 3), and febrile neutr

104 s reported in more than 10% of patients were somnolence (n=41 [25%]), decreased appetite (n=31 [19%])

105 e brexanolone group (sinus tachycardia, n=1; somnolence, n=1) and in two patients in the placebo grou

106 Somnolence, nausea, and dizziness were the most common s

107 thy range from mild confusion and aphasia to somnolence, obtundation, and in some cases seizures and

108 rely symptomatic hyponatremia (with signs of somnolence, obtundation, coma, seizures, or cardiorespir

109 Reversible somnolence or stupor occurred in 3 patients at arginine

110 53), diarrhoea (OR 2.61, 95% CI: 1.46-4.67), somnolence (OR 2.23, 95% CI: 1.07-4.64) and sedation (OR

111 ed with memory difficulty, minor depression, somnolence, or headache.

112 group, 23 [31%]; CBD50 group, 41 [56%]) and somnolence (placebo group, 7 [9%]; CBD25 group, 10 [13%]

113 Somnolence, pyrexia, and upper respiratory tract infecti

114 There was no grade 3/4 somnolence reported.

115 95% CI, 2.23-14.39; I2 = 0%; 6 trials), and somnolence (RR, 2.28; 95% CI, 1.83-2.85; I2 = 8%; 14 tri

116 ciations with abnormal liver function tests, somnolence, sedation and pneumonia were limited to child

117 an in the olanzapine plus placebo group were somnolence, sedation, dizziness, and constipation.

118 ssness, anxiety, depression, suicidality and somnolence/sedation.

119 ents receiving apomorphine sublingual film), somnolence (seven [13%]), and dizziness (five [9%]).

120 ]), weight gain (zero [0%] vs one [1%]), and somnolence (six [5%] vs five [4%]) were similar between

121 storical descriptions of EL: sleep disorder (somnolence, sleep inversion or insomnia), lethargy, park

122 xisting agents effective at reducing daytime somnolence (such as modafinil) hold potential for the tr

123 eported treatment-emergent adverse event was somnolence (ten [16%] with valbenazine, two [3%] with pl

124 The dose was reduced because of somnolence to 600 mg for five patients and to 400 mg for

125 enidate is used to ameliorate opioid-induced somnolence, to augment the analgesic effects of opioids,

126 quently reported for lurasidone were nausea, somnolence, tremor, akathisia, and insomnia.

127 vs three patients in the placebo group) and somnolence (two vs none).

128 rated dose-dependent increases in subjective somnolence (via Karolinska Sleepiness Scale and Visual A

129 Grade 1/2 somnolence was greater in the olanzapine group (35% v 11

130 al symptoms was similar between groups, more somnolence was observed with quetiapine (22% vs. 11%; p

131 Grade 1 somnolence was reported by 27 patients (10%) following a

132 Somnolence was significantly more common among patients

133 ed at least one adverse effect of treatment; somnolence was the most frequent.

134 Somnolence was usually mild and transient.

135 The most common adverse event, somnolence, was reported for 69 patients (13%) who recei

136 The incidences of somnolence, weight gain, restlessness, and extrapyramida

137 The occurrence of adverse drug reactions and somnolence were observed in 19.7% and 15.2% of the subje

138 cases of dry mouth, increased appetite, and somnolence were reported with olanzapine, while more cas

139 of extrapyramidal symptoms, weight gain, and somnolence were similar between treatment groups.

140 Dizziness and somnolence were the most frequent adverse events.

141 Reversible symptoms of fatigue and somnolence were the primary toxicities, with only mild h

142 ing abnormal dreams, anxiety, dizziness, and somnolence) were significantly more common in the EFV-TD

143 iclone and zolpidem whereby DORA-22 promotes somnolence without altering the neuronal network EEG act